When Validation Becomes the Bottleneck
Why Large Capital Projects Need a Different Operating Model In large pharmaceutical capital projects, speed is always a priority. But one part of the process
Validation
From Uncertainty to Reality: Validating AI and Gen AI in the Pharmaceutical Industry
Conversations That Matter No deviation’s Takeaways from 2025 ISPE France Conference – Validation of AI in the pharmaceutical industry. Presentation of a validation strategy for
Harmonisation of Global Standards with China’s (NMPA) Regulatory Landscape
With No deviation now established in China, we’re taking a closer look at China’s regulatory landscape and its global connections. Understanding how the NMPA (National
An overview of the ISPE Good Practice Guide (GPG) for Digital Validation
Conversations That Matter No deviation’s Takeaways from 2025 ISPE Conference in Singapore Speaker: Dave O’Connor, C&Q Digital Transformation Manager at No deviation, One of the
Case Study: How No deviation Helped Achieve a Smooth Kneat Upgrade (v8.8 to v9.3)
A leading pharmaceutical client, using Kneat since 2019, partnered with No deviation for a critical upgrade from version 8.8 to 9.3. Their goal: improve system
ISPE’s Good Practice Guide is out — and No deviation Is Proudly Involved
Digital Validation Takes Center Stage April 2025 marks a major milestone in the pharmaceutical and life sciences industries: the publication of ISPE’s Good Practice Guide:
Upgrade of Kneat SAAS Platform – Why It Matters and How to Succeed
The pharmaceutical industry is under constant pressure to deliver safe, compliant products while accelerating time-to-market. Traditional paper-based validation processes are time-consuming, error-prone, and difficult to
